More about Krishna Institute of Medical Sciences Limited
Fundamentals for Krishna Institute of Medical Sciences Limited
Regulatory Filings for Krishna Institute of Medical Sciences Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Krishna Institute of Medical Sciences Limited
Business Operations:
Sector: HealthcareIndustry: Medical Care Facilities
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, Alzheimer's, bone, joint center specialties, and others. In addition, the company provides medical procedures for aneurysm, ankle arthritis and total ankle replacement, anterior cervical discectomy and fusion surgery, anterior resection, aortic aneurysm, aortic stent graft, aortic valve replacement, arthroscopy, atrial septal defect, bariatric surgery, and others. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
Revenue projections:
With KIMS's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 52.071507 |
| debtToEquity | 123.719000 |
| earningsGrowth | -0.401000 |
| revenueGrowth | 0.292000 |
| grossMargins | 0.595950 |
| operatingMargins | 0.120480 |
| trailingEps | 7.480000 |
| forwardEps | 13.299020 |
KIMS's elevated forward PE ratio indicates that the stock may face limited price growth and is at risk for a correction. Investors should consider this metric alongside other fundamentals to accurately assess the stock's valuation.
Krishna Institute of Medical Sciences Limited's high debt-to-equity ratio shows the company is significantly leveraged, relying heavily on debt financing. This raises the potential for increased financial risk, especially if the company's earnings or cash flow are negatively impacted.
KIMS's low earnings and revenue growth indicate potential profit shrinkage. This suggests that the company's financial performance may be weakening, raising concerns about its future profitability and overall business outlook.
KIMS's negative gross and operating margins suggest the company is not generating profit from either its production process or day-to-day operations. This could signal cost overruns or difficulties in maintaining revenue levels.
KIMS's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that KIMS's financial performance will improve in the current financial year.
Price projections:
The stock price of Krishna Institute of Medical Sciences Limited has frequently been close to the lower end of analysts' projections. This trend indicates potential struggles for the company in achieving the growth anticipated by the market.
Recommendation changes over time:
The recent buy bias from analysts suggests Krishna Institute of Medical Sciences Limited is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, Krishna Institute of Medical Sciences Limited appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape